持田製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2022/07/12 | 3,385 | 3,400 | 3,320 | 3,340 | -60 | -1.8% | 33,100 |
2022/07/11 | 3,370 | 3,425 | 3,370 | 3,400 | +65 | +1.9% | 35,700 |
2022/07/08 | 3,355 | 3,385 | 3,295 | 3,335 | -20 | -0.6% | 59,100 |
2022/07/07 | 3,340 | 3,370 | 3,320 | 3,355 | +55 | +1.7% | 43,500 |
2022/07/06 | 3,280 | 3,315 | 3,275 | 3,300 | +20 | +0.6% | 36,100 |
2022/07/05 | 3,290 | 3,300 | 3,260 | 3,280 | ±0 | ±0% | 35,300 |
2022/07/04 | 3,300 | 3,325 | 3,275 | 3,280 | +30 | +0.9% | 33,500 |
2022/07/01 | 3,265 | 3,300 | 3,225 | 3,250 | -15 | -0.5% | 36,200 |
2022/06/30 | 3,285 | 3,335 | 3,250 | 3,265 | -15 | -0.5% | 53,800 |
2022/06/29 | 3,250 | 3,290 | 3,230 | 3,280 | +5 | +0.2% | 74,200 |
2022/06/28 | 3,200 | 3,280 | 3,190 | 3,275 | +45 | +1.4% | 49,300 |
2022/06/27 | 3,265 | 3,265 | 3,175 | 3,230 | ±0 | ±0% | 43,600 |
2022/06/24 | 3,215 | 3,235 | 3,180 | 3,230 | +30 | +0.9% | 31,200 |
2022/06/23 | 3,180 | 3,210 | 3,170 | 3,200 | +30 | +0.9% | 31,100 |
2022/06/22 | 3,175 | 3,185 | 3,155 | 3,170 | +35 | +1.1% | 38,000 |
2022/06/21 | 3,165 | 3,180 | 3,110 | 3,135 | +5 | +0.2% | 48,200 |
2022/06/20 | 3,145 | 3,170 | 3,130 | 3,130 | -5 | -0.2% | 50,200 |
2022/06/17 | 3,060 | 3,145 | 3,060 | 3,135 | +20 | +0.6% | 84,200 |
2022/06/16 | 3,110 | 3,145 | 3,095 | 3,115 | +50 | +1.6% | 42,900 |
2022/06/15 | 3,095 | 3,100 | 3,060 | 3,065 | -35 | -1.1% | 36,300 |
2022/06/14 | 3,095 | 3,135 | 3,095 | 3,100 | -35 | -1.1% | 39,800 |
2022/06/13 | 3,100 | 3,145 | 3,095 | 3,135 | -10 | -0.3% | 33,900 |
2022/06/10 | 3,160 | 3,185 | 3,140 | 3,145 | -60 | -1.9% | 49,700 |
2022/06/09 | 3,175 | 3,220 | 3,175 | 3,205 | ±0 | ±0% | 38,100 |
2022/06/08 | 3,190 | 3,220 | 3,175 | 3,205 | +75 | +2.4% | 55,100 |
2022/06/07 | 3,135 | 3,145 | 3,110 | 3,130 | -5 | -0.2% | 46,800 |
2022/06/06 | 3,110 | 3,145 | 3,110 | 3,135 | +30 | +1% | 40,400 |
2022/06/03 | 3,120 | 3,150 | 3,100 | 3,105 | -15 | -0.5% | 37,500 |
2022/06/02 | 3,170 | 3,170 | 3,095 | 3,120 | -20 | -0.6% | 63,900 |
2022/06/01 | 3,125 | 3,175 | 3,120 | 3,140 | +40 | +1.3% | 61,100 |
2022/05/31 | 3,115 | 3,125 | 3,050 | 3,100 | -15 | -0.5% | 187,300 |
2022/05/30 | 3,085 | 3,140 | 3,055 | 3,115 | +60 | +2% | 124,500 |
2022/05/27 | 3,070 | 3,075 | 3,025 | 3,055 | +5 | +0.2% | 67,800 |
2022/05/26 | 3,070 | 3,095 | 3,050 | 3,050 | -20 | -0.7% | 59,300 |
2022/05/25 | 3,085 | 3,115 | 3,055 | 3,070 | -20 | -0.6% | 48,000 |
2022/05/24 | 3,100 | 3,135 | 3,065 | 3,090 | -70 | -2.2% | 71,100 |
2022/05/23 | 3,140 | 3,170 | 3,100 | 3,160 | +55 | +1.8% | 62,900 |
2022/05/20 | 3,050 | 3,115 | 3,050 | 3,105 | +55 | +1.8% | 76,200 |
2022/05/19 | 3,130 | 3,130 | 3,030 | 3,050 | -105 | -3.3% | 84,100 |
2022/05/18 | 3,165 | 3,185 | 3,130 | 3,155 | -10 | -0.3% | 54,800 |
2022/05/17 | 3,220 | 3,285 | 3,160 | 3,165 | +5 | +0.2% | 72,900 |
2022/05/16 | 3,365 | 3,415 | 3,150 | 3,160 | -175 | -5.2% | 128,300 |
2022/05/13 | 3,465 | 3,495 | 3,305 | 3,335 | -200 | -5.7% | 108,900 |
2022/05/12 | 3,625 | 3,640 | 3,525 | 3,535 | -160 | -4.3% | 40,500 |
2022/05/11 | 3,685 | 3,715 | 3,640 | 3,695 | +10 | +0.3% | 40,800 |
2022/05/10 | 3,695 | 3,725 | 3,650 | 3,685 | +35 | +1% | 64,600 |
2022/05/09 | 3,765 | 3,765 | 3,650 | 3,650 | -75 | -2% | 41,000 |
2022/05/06 | 3,705 | 3,750 | 3,695 | 3,725 | +30 | +0.8% | 34,200 |
2022/05/02 | 3,655 | 3,710 | 3,655 | 3,695 | -5 | -0.1% | 35,400 |
2022/04/28 | 3,545 | 3,700 | 3,545 | 3,700 | +175 | +5% | 49,300 |
701~
750
件表示中 / 3705件
類似銘柄と比較する
現在ご覧いただいている「持田薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
持田薬 | 297,600円 | +5.1% | -7.0% | 2.69% | 19.54倍 | 0.81倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ジーエヌアイ | 297,100円 | +21.7% | +999.9% | 0.00% | 12.45倍 | 4.12倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
ゼリア新薬 | 213,700円 | +3.1% | -6.5% | 2.25% | 9.92倍 | 1.05倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
杏林製薬 | 146,000円 | -2.4% | -52.3% | 3.90% | 17.47倍 | 0.62倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
栄研化 | 200,000円 | +4.1% | -3.1% | 2.90% | 17.54倍 | 1.53倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム